[Ultiva (remifentanil hydrochloride), intravenous dose of 2mg, 5mg: pharmacological and clinical profile].
Nomura
Shunji
S
Arai
Tsutomu
T
Takeuchi
Satoshi
S
Masui
Akinori
A
Wakamatsu
Akihide
A
Harada
Yasushi
Y
D000701:Analgesics, Opioid / Q000008:administration & dosage* / Q000494:pharmacology*; D000768:Anesthesia, General; D018685:Anesthetics, Inhalation; D018686:Anesthetics, Intravenous / Q000008:administration & dosage* / Q000494:pharmacology*; D000818:Animals; D017326:Clinical Trials, Phase III as Topic; D004338:Drug Combinations; D006801:Humans; D007262:Infusions, Intravenous; D008738:Methyl Ethers; D010880:Piperidines / Q000008:administration & dosage* / Q000494:pharmacology*; D015742:Propofol; D017450:Receptors, Opioid, mu / Q000819:agonists / Q000378:metabolism; D000077208:Remifentanil; D000077149:Sevoflurane
D000701:Analgesics, Opioid; D018685:Anesthetics, Inhalation; D018686:Anesthetics, Intravenous; D004338:Drug Combinations; D008738:Methyl Ethers; D010880:Piperidines; D017450:Receptors, Opioid, mu; D000077149:Sevoflurane; D000077208:Remifentanil; D015742:Propofol